Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Recent findings in cancer vaccines described by researchers from University of Lubeck, Medical Department
May 27th, 2008
"Standard systemic treatment of prostate cancer today is comprised of antihormonal and cytostatic agents. Vaccine therapy of prostate cancer is principally attractive because of the presence of tumor-associated antigens such as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA), and others," scientists in Lubeck, Germany report. "Most prostate cancer vaccine trials have demonstrated some activation of the immune system, limited clinical success, and few adverse effects. One strategy to overcome the problem of limited clinical success of vaccine therapies in prostate cancer could be strict patient selection. The...
Source: Cancer Weekly (2008-05-27)
|
